Doctor profile · Federal record

Dr. Emily Overholser, M.D.

Dermatology Physician (CMS: Dermatology) · Memphis, TN

  • NPI 1073824561
  • Accepts Medicare
  • MIPS 88.5 / 100 · 2023
  • 16 yrs in practice
  • Female
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
1455 Union Ave
Memphis, TN 381046727
(901) 726-6655
fax (901) 726-9056
Mailing address
1655 Vera Cruz St
Memphis, TN 381177303

Credentials & registration

NPPES · NUCC
NPI registered
June 2010 — 16 yrs on file
Profile last updated
June 27, 2014
Year of graduation
2010 — 16 yrs since
Specialty taxonomy
207N00000X — NUCC code
State license (1)
Tennessee #51433

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1073824561. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
9,067
Distinct HCPCS
10
Medicare allowed
$973,765
HCPCS Description Services Patients Avg allowed
J3245 Injection, tildrakizumab, 1 mg 5,700 19 $138
17003 Destruction of precancer skin growth, 2-14 growths 1,122 161 $6
99213 Established patient office or other outpatient visit, 20-29 minutes 607 422 $84
11102 Biopsy of related skin growth, first growth 267 223 $81
17000 Destruction of precancer skin growth, 1 growth 259 204 $44
17110 Destruction of skin growth, 1-14 growths 227 196 $101
11103 Biopsy of related skin growth, each additional growth 190 103 $45
99203 New patient office or other outpatient visit, 30-44 minutes 134 134 $105
96372 Injection of drug or substance under skin or into muscle 89 31 $13
99212 Established patient office or other outpatient visit, 10-19 minutes 78 73 $53

In context: peer comparison

Among 5 peers in Memphis Dermatology Physician, average services per provider: 314. This provider delivers 29× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$76,619
Transactions
201
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Abbvie INC. 95 $57,902.29
Incyte Corporation 20 $16,771.47
Genzyme Corporation 11 $393.85
Janssen Biotech, INC. 16 $374.27
E.R. Squibb & Sons, L.L.C. 11 $162.62
Novartis Pharmaceuticals Corporation 8 $160.96
Arcutis Biotherapeutics, INC. 9 $159.68
Sun Pharmaceutical Industries INC. 7 $157.37
Ucb, INC. 6 $135.88
Lilly USA, LLC 6 $131.92
Regeneron Healthcare Solutions, INC. 3 $91.33
Dermavant Sciences, INC. 4 $60.87
Leo Pharma INC. 3 $56.72
Galderma Laboratories, L.P. 1 $19.91
Organogenesis INC. 1 $19.82

By nature of payment

Compensation for Services Other Than Consulting, Including Serving As Faculty or As A Speaker at A Venue Other Than A Continuing Education Program
$65,245
Travel and Lodging
$5,496
Food and Beverage
$4,432
Consulting Fee
$1,350
Education
$96

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
692
Patients
364
Total drug cost
$184,126
Drug Type Claims Patients Total cost
Ketoconazole Generic 197 109 $2,754
Minoxidil Generic 83 29 $686
Triamcinolone Acetonide Generic 58 43 $955
Mupirocin Generic 47 37 $554
Doxycycline Hyclate Generic 46 24 $1,640
Fluocinonide Generic 43 30 $2,402
Mycophenolate Mofetil Generic 30 0 $5,558
Tacrolimus Generic 30 20 $4,500
Prednisone Generic 28 13 $117
Doxycycline Monohydrate Generic 27 15 $932

Frequently asked questions

Auto-generated from federal data
What is Dr. Emily Overholser's medical specialty?
Dr. Emily Overholser practices Dermatology Physician in Memphis, TN.
Where does Dr. Emily Overholser practice?
Dr. Emily Overholser practices at 1455 Union Ave, Memphis, TN 381046727. Office phone: 9017266655.
What is Dr. Emily Overholser's NPI?
Dr. Emily Overholser's National Provider Identifier (NPI) is 1073824561, issued by NPPES.
Does Dr. Emily Overholser accept Medicare assignment?
Yes. Dr. Emily Overholser accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Emily Overholser commonly perform?
Top Medicare-reported procedures in 2023: Injection, tildrakizumab, 1 mg (HCPCS J3245); Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99213). Source: CMS Medicare Physician & Other Practitioners file.